© Globe Newswire
01.08.2024
FAGR
LISTED
EURONEXT
Fagron delivers strong performance with 16% topline growth and 17% increase in REBITDA for the first half of 2024
News Preview
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 1 August 2024 – 7:00 AM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.08.2024
IBAB
LISTED
EURONEXT
IBA Notice of Half Year 2024 Results and Conference Call
News Preview
HY24 results webcast to take place on Thursday, 29 August 2024 at 3pm CEST...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2024
ORY
LISTED
BME
ORYZON reports financial results and corporate update for half-year ending June 30, 2024
News Preview
MADRID and CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the half-year ending June 30, 2024 and provided a corporate upd...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
31.07.2024
MURA
LISTED
NASDAQ
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors
News Preview
WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of George Golumbeski, Ph.D., to its...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
31.07.2024
1SXP
LISTED
XETR
SCHOTT Pharma introduces nest design with more cavities for prefillable polymer syringes
News Preview
Transforming operational efficiency and sustainability: SCHOTT Pharma introduces nest design with more cavities for prefillable polymer syringes
31 July 2024, Germany, Mainz
SCHOTT Pharma’s new nest holds 160 prefillable polymer syringes, which marks an increase of 60 syringes per nest.
The new nest design allows pharma companies to increase the......
Themefolio
Profiler
Peergroup
© EQS Newswire
31.07.2024
1SXP
LISTED
XETR
SCHOTT Pharma führt neues Nestdesign mit erhöhter Anzahl an vorfüllbaren Polymerspritzen ein
News Preview
Effizient und nachhaltig: SCHOTT Pharma führt neues Nestdesign mit erhöhter Anzahl an vorfüllbaren Polymerspritzen ein
31. Juli 2024, Deutschland, Mainz
Neues Nest von SCHOTT Pharma bietet bei gleichbleibenden Außenmaßen Platz für 160 anstelle von 100 vorfüllbare Polymerspritzen
Dank verändertem Design können Pharmaunternehmen ihre Effizienz um ......
Themefolio
Profiler
Peergroup
© Newsfile
31.07.2024
COPN
LISTED
SIX
Cosmo Intelligent Medical Devices Unveils Next Generation GI Genius(TM) Hardware with New FDA Clearance
News Preview
Dublin, Ireland--(Newsfile Corp. - July 31, 2024) - Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) focused on pioneering medical devices powered by Artificial Intelligence, announced today that the U.S. Food and Drug Administration (FDA) has granted 510...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.07.2024
DBV
LISTED
EURONEXT
DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report
News Preview
Châtillon, France, July 30, 2024...
Themefolio
Profiler
Peergroup
© EQS Newswire
30.07.2024
FYB
LISTED
XETR
Formycon gibt Start der klinischen Phase-III-Studie für den Keytruda® Biosimilar-Kandidaten FYB206 bekannt
News Preview
Pressemitteilung // 30. Juli 2024
Formycon gibt Start der klinischen Phase-III-Studie für den Keytruda® Biosimilar-Kandidaten FYB206 bekannt
Phase-III-Studie „Lotus“ vergleicht Sicherheit und Wirksamkeit von FYB206 mit Referenzarzneimittel Keytruda®1 (Pembrolizumab)
„Lotus“-Studie sieht Behandlung von rund 500 randomisierten NSCLC2-Patienten......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.07.2024
FYB
LISTED
XETR
Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
News Preview
Press Release // July 30, 2024
Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
Phase III “Lotus” trial compares safety and efficacy of FYB206 with reference drug Keytruda®1 (pembrolizumab)
The “Lotus” trial will involve the treatment of around 500 randomized NSCLC2 patients in various countries ......
Themefolio
Profiler
Peergroup
© Globe Newswire
29.07.2024
ZEAL
LISTED
CPH
Zealand Pharma Appoints Eric Cox as Chief Commercial Officer
News Preview
Press release – 7 / 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.07.2024
DBV
LISTED
EURONEXT
DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024
News Preview
Châtillon, France, July 29, 2024...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
26.07.2024
MRK
LISTED
XETR
Strong 2nd Quarter, Guidance raised
News Preview
Darmstadt, July 26, 2024: Based on a very strong second quarter of 2024 with net sales of EUR 5.352 bn resulting in an EBITDA pre1 of EUR 1.509 bn and an EPS pre1 of EUR 2.20, Merck KGaA (the "Company") has further raised its forecast for the entire group for fiscal 2024. The main driver is a very strong operating performance of Healthcare and Ele......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.07.2024
MRK
LISTED
XETR
Starkes 2. Quartal, Anhebung der Prognose
News Preview
Darmstadt, 26. Juli 2024: Basierend auf einem sehr starken zweiten Quartal 2024 mit netto Umsätzen in Höhe von EUR 5,352 Mrd., einem EBITDA pre1 in Höhe von EUR 1,509 Mrd. sowie EPS pre1 in Höhe von EUR 2,20, hat die Merck KGaA (die "Gesellschaft") ihre Prognose für die Gruppe für das Geschäftsjahr 2024 angehoben. Der Haupttreiber für die Anhebung ......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.07.2024
FYB
LISTED
XETR
Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®
News Preview
Press Release // July 26, 2024
Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommends approval of FYB202 for the treatment of severe inflammatory diseases in the fields of gastroente......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.07.2024
FYB
LISTED
XETR
Formycon und Fresenius Kabi erhalten positive CHMP-Empfehlung für FYB202 (Ustekinumab), einen Biosimilar-Kandidaten für Stelara®
News Preview
Pressemitteilung // 26. Juli 2024
Formycon und Fresenius Kabi erhalten positive CHMP-Empfehlung für FYB202 (Ustekinumab), einen Biosimilar-Kandidaten für Stelara®
Ausschuss für Humanarzneimittel (CHMP) der europäischen Arzneimittel-Agentur empfiehlt Zulassung von FYB202 für die Behandlung schwerwiegender inflammatorischer Erkrankungen aus den......
Themefolio
Profiler
Peergroup
© Globe Newswire
26.07.2024
POAI
LISTED
NASDAQ
Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds
News Preview
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 958,117 shares of its common stock having a current exercise price of $...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.07.2024
AUTL
LISTED
NASDAQ
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
News Preview
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.07.2024
LEGN
LISTED
NASDAQ
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
News Preview
SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced preliminary, unaudited financial results for the six-months ended June 30, 2024....
Themefolio
Profiler
Peergroup
© EQS Newswire
26.07.2024
FYB
LISTED
XETR
Stelara® Biosimilar-Kandidat FYB202 (Ustekinumab) erhält CHMP-Empfehlung der EMA
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014
Stelara® Biosimilar-Kandidat FYB202 (Ustekinumab) erhält CHMP-Empfehlung der EMA
Planegg-Martinsried, Deutschland, 26. Juli 2024 – Die Formycon AG (FWB: FYB, "Formycon“) gibt bekannt, dass der Ausschuss für Humanarzneimittel (Committee for Medicinal Product......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.07.2024
FYB
LISTED
XETR
Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA
News Preview
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014
Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA
Planegg-Martinsried, Germany, July 26, 2024 – Formycon AG (FSE: FYB, "Formycon“) announces that the Committee for Medicinal Products for Human Use („CHMP“) of the Eu......
Themefolio
Profiler
Peergroup
© Globe Newswire
26.07.2024
BAVA
LISTED
CPH
Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine
News Preview
COPENHAGEN, Denmark, July 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a type II variation for IMVANEX® (MVA-BN) smallpox and mpox vaccine, including real-world effectiveness data from the use of the va...
Themefolio
Profiler
Peergroup
© PR Newswire
25.07.2024
ATNM
LISTED
XASE
Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University
News Preview
- Sickle cell disease affects approximately 100,000 patients in the U.S. annually and is a debilitating and life-threatening condition with high unmet need
- Current conditioning with non-targeted chemotherapies provides limited access to potentially curative bone marrow transplant and recently approved gene therapies for sickle cell disease pati...
Themefolio
Profiler
Peergroup
© PR Newswire
25.07.2024
ATNM
LISTED
XASE
Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US
News Preview
Presentation to highlight positive outcomes of Iomab-B led bone marrow transplant in difficult to treat TP53 patients and the mutation-agnostic mechanism of Actimab-A for patients with relapsed or refractory acute myeloid leukemiaIomab-B and Actimab-A represent the only clinical stage antibody radiation conjugates in development for patients with...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2024
POAI
LISTED
NASDAQ
Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
News Preview
Expands AI/ML driven offering to include novel oncology biomarker discovery to predict patient outcomes and drug response in oncology...
Themefolio
Profiler
Peergroup
© PR Newswire
25.07.2024
INDV
LISTED
NASDAQ
Indivior Announces a New $100 Million Share Repurchase Program; New Program will be Executed Over an Accelerated Time Frame
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
Repurchases Under Current Program now Expected to be Completed by End of JulyRICHMOND, Va., July 25, 2024 /PRNewswire/ -- Indiv...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2024
ORNBV
LISTED
HEL
Orion publishes Half-Year Financial Report for January–June 2024 and holds a webcast on 8 August 2024
News Preview
ORION CORPORATION PRESS RELEASE 25 JULY 2024 at 11.00 EEST...
Themefolio
Profiler
Peergroup
© PR Newswire
25.07.2024
INDV
LISTED
NASDAQ
Indivior Announces Q2 2024 Financial Results
News Preview
SLOUGH, UK and RICHMOND, Va., July 25, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending June 30, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com....
Themefolio
Profiler
Peergroup
© PR Newswire
25.07.2024
INDV
LISTED
NASDAQ
Indivior Announces Q2 2024 Financial Results
News Preview
SLOUGH, UK and RICHMOND, Va., July 25, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending June 30, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com.
The earnings release can be found at www.indivior.com/investorsThe investor presentation...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.07.2024
MDGL
LISTED
NASDAQ
Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024
News Preview
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.07.2024
SKYE
LISTED
NASDAQ
Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
News Preview
Skye introduces collaboration with Beacon Biosignals to evaluate potential impact of Nimacimab on sleep quality and sleep apnea Skye introduces collaboration with Beacon Biosignals to evaluate potential impact of Nimacimab on sleep quality and sleep apnea...
Themefolio
Profiler
Peergroup
© Newsfile
24.07.2024
COPN
LISTED
SIX
Cosmo Achieves Robust Financial Performance in H1 2024 and Confirms Its Full Year Guidance
News Preview
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - July 24, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced its 2024 half year results. Key highlights Health Tech: Upfront payment of $100 million received from Medtron...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.07.2024
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis
News Preview
OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.07.2024
INSP
LISTED
NYSE
Inspire Medical Systems, Inc. Announces Countrywide Reimbursement in France
News Preview
MINNEAPOLIS, July 23, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), announced today the publication of the reimbursement of Inspire therapy in F...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.07.2024
INSP
LISTED
NYSE
Inspire Medical Systems, Inc. Announces the Appointment of Melissa J. Mann as Chief People Officer
News Preview
MINNEAPOLIS, July 22, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today the addition of Melissa J. Mann as Chief People Officer, effective...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.07.2024
INSP
LISTED
NYSE
Inspire Medical Systems, Inc. Announces CE Mark Certification under the European Union’s Medical Device Regulation for Inspire Therapy
News Preview
MINNEAPOLIS, July 19, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced CE mark certification under the European Union’s Medical Dev...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.07.2024
INSP
LISTED
NYSE
Inspire Medical Systems, Inc. Announces CE Mark Certification of Full-Body MRI Compatibility under the European Union’s Medical Device Regulation
News Preview
MINNEAPOLIS, July 19, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that the European Union Medical Device Regulation (EU MDR) h...
Themefolio
Profiler
Peergroup
© EQS Newswire
18.07.2024
SRT3
LISTED
XETR
Moderat positive Umsatzentwicklung im 2. Quartal; Nachfrageerholung weiterhin verhalten; Gesamtjahresausblick bewusst vorsichtiger; langfristige Trends unverändert positiv
News Preview
Göttingen, 18. Juli 2024
Ergebnisse 1. Halbjahr: Moderat positive Umsatzentwicklung im 2. Quartal; Nachfrageerholung weiterhin verhalten; Gesamtjahresausblick bewusst vorsichtiger; langfristige Trends unverändert positiv
Umsatz nach sechs Monaten noch leicht rückläufig mit – 2,2 Prozent; Wachstum von 3,6 Prozent im zweiten Quartal
Operative Ert......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.07.2024
SRT3
LISTED
XETR
Moderately positive revenue development in the second quarter; demand recovery remains muted, full-year outlook deliberately more cautious; long-term trends remain positive
News Preview
Göttingen, July 18, 2024
Half-year results: Moderately positive revenue development in the second quarter; demand recovery remains muted, full-year outlook deliberately more cautious; long-term trends remain positive
Sales revenue slightly down 2.2 percent after six months; growth of 3.6 percent in second quarter
Underlying EBITDA margin at a ......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.07.2024
SRT3
LISTED
XETR
Sartorius AG passt Prognose für das Geschäftsjahr 2024 an und legt Geschäftszahlen zum ersten Halbjahr 2024 vor
News Preview
Veröffentlichung einer Insiderinformation gemäß Artikel 17 MAR
Sartorius AG passt Prognose für das Geschäftsjahr 2024 an und legt Geschäftszahlen zum ersten Halbjahr 2024 vor
Der Life-Science-Konzern Sartorius hat in einem anhaltend sehr herausfordernden und volatilen Marktumfeld das erste Halbjahr mit einem positiven Trend bei der Umsatzentwickl......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.07.2024
SRT3
LISTED
XETR
Sartorius AG adjusts its guidance for fiscal year 2024 and presents results for H1 2024
News Preview
Disclosure of inside information according to Article 17 MAR
Sartorius AG adjusts its guidance for fiscal year 2024 and presents results for H1 2024
In a continuously very challenging and volatile market environment, the life science group Sartorius closed the first half of the year with a positive trend in sales revenue development. In view of t......
Themefolio
Profiler
Peergroup
© Newsfile
18.07.2024
CTXR
LISTED
NASDAQ
Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
News Preview
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com, a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercializati...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.07.2024
BAVA
LISTED
CPH
Bavarian Nordic Receives EMA Filing Acceptance and Validation of the MAA for its Chikungunya Vaccine
News Preview
COPENHAGEN, Denmark, July 18, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA), which was submitted in June 2024 for CHIKV VLP, the Company’s vaccine candidate for immunization to prevent disease caused by chikungunya virus infection in indivi...
Themefolio
Profiler
Peergroup
© Newsfile
17.07.2024
CTXR
LISTED
NASDAQ
Analysts Hunt for Undervalued Biotech Stocks
News Preview
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 17, 2024) - Investorideas.com, a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercializatio...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2024
OXB
LISTED
LSE
Oxford Biomedica announces CFO transition
News Preview
Oxford Biomedica announces Chief Financial Officer transition...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2024
GMAB
LISTED
CPH
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.07.2024
KDEV
LISTED
STO
Karolinska Development’s portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator
News Preview
STOCKHOLM, SWEDEN – July 16, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that portfolio company PharmNovo has been granted funding of EUR 17.5 million from the European Innovation Council (EIC) Accelerator, a part of the Horizon Europe innovation support program. The funding consists of a grant of EUR 2.5 million and co...
Themefolio
Profiler
Peergroup
© EQS Newswire
16.07.2024
EUZ
LISTED
XETR
Eckert & Ziegler mit erneutem Umsatz- und Gewinnsprung gegenüber Vorjahr. Gewinnprognose für 2024 angehoben.
News Preview
2. Quartal 2024:
Umsatz: 77,8 Mio. EUR (VJ: 60,1 Mio. EUR)
EBIT vor Sondereinflüssen: 17,5 Mio. EUR (VJ: 12,0 Mio. EUR)
Nettogewinn: 9,5 Mio. EUR (VJ: 6,2 Mio. EUR)
1. Halbjahr 2024:
Umsatz: 145,4 Mio. EUR (VJ: 118,0 Mio. EUR)
EBIT vor Sondereinflüssen: 32,5 Mio. EUR (VJ: 22,6 Mio. EUR)
Nettogewinn: 18,0 Mio. EUR (VJ: 10,9 Mio. EUR)
Jahrespro......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.07.2024
EUZ
LISTED
XETR
Eckert & Ziegler Again Increases Sales and Earnings Compared to Previous Year. Profit Forecast Raised for 2024.
News Preview
2nd quarter of 2024:
Sales of EUR 77.8 million (previous year: EUR 60.1 million)
EBIT before special items of EUR 17.5 million (previous year: EUR 12.0 million)
Net income of EUR 9.5 million (previous year: EUR 6.2 million)
1st half of 2024:
Sales of EUR 145.4 million (previous year: EUR 118.0 million)
EBIT before special items of EUR 32.5 mi......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.07.2024
1SXP
LISTED
XETR
SCHOTT Pharma bringt vorsterilisierte großvolumige Karpulen für tragbare Injektoren auf den Markt
News Preview
Subkutane Selbstmedikation fördern: SCHOTT Pharma bringt vorsterilisierte großvolumige Karpulen für tragbare Injektoren auf den Markt
16. Juli 2024, Deutschland, Mainz
Die neuen vorsterilisierten 10 ml-Karpulen von SCHOTT Pharma eignen sich insbesondere zur Aufbewahrung hochsensibler Biologika, die u.a. zur Behandlung von Krebs, Stoffwechselstöru......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.07.2024
1SXP
LISTED
XETR
SCHOTT Pharma launches large format ready-to-use cartridges for on-body devices
News Preview
Driving subcutaneous self-injection of large volume doses: SCHOTT Pharma launches large format ready-to-use cartridges for on-body devices
16 July 2024, Germany, Mainz
SCHOTT Pharma introduces new 10ml ready-to-use (RTU) cartridges, specifically designed to store highly sensitive biologics used to treat cancer, metabolic disorders, cardiovascular......
Themefolio
Profiler
Peergroup
© Newsfile
11.07.2024
CTXR
LISTED
NASDAQ
Bloodstream Infections - From Threats to Solutions
News Preview
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company ded...
Themefolio
Profiler
Peergroup
© Newsfile
11.07.2024
CTXR
LISTED
NASDAQ
Biopharma Stocks Transformative Innovation for the Future of Health
News Preview
Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the first of a two-part series looking at transformative innovation in biopharma, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and com...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.07.2024
SKYE
LISTED
NASDAQ
Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th
News Preview
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that it will host a virtual KOL event entitled “Metabolic Rew...
Themefolio
Profiler
Peergroup
© EQS Newswire
11.07.2024
GXI
LISTED
XETR
Gerresheimer bleibt im 1. Halbjahr 2024 auf Kurs
News Preview
Gerresheimer bleibt im 1. Halbjahr 2024 auf Kurs
Organisches Wachstum: Umsatz +1,7 %, Adjusted EBITDA +2,9 %
Geschäftsbereich Plastics & Devices mit gutem Umsatzwachstum und deutlich verbesserter Marge
Prognose bestätigt
Düsseldorf, 11. Juli 2024. Gerresheimer, innovativer System- und Lösungsanbieter und globaler Partner für die Pharma-, Bio......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.07.2024
GXI
LISTED
XETR
Gerresheimer remains on track in 1st half year 2024
News Preview
Gerresheimer remains on track in 1st half year 2024
Organic growth: revenues +1.7%, adjusted EBITDA +2.9%
Plastics & Devices division with good revenue growth and significantly improved margin
Guidance confirmed
Düsseldorf (Germany), July 11, 2024. Gerresheimer, an innovative systems & solutions provider and global partner for the pharma......
Themefolio
Profiler
Peergroup
© Globe Newswire
10.07.2024
LEGN
LISTED
NASDAQ
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
News Preview
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results....
Themefolio
Profiler
Peergroup
© EQS Newswire
10.07.2024
EVT
LISTED
XETR
Evotec und Pfizer arbeiten zusammen, um Wirkstoffforschung in Frankreich voranzubringen
News Preview
Die mehrjährige Zusammenarbeit wird sich zunächst auf die frühe Forschung und Entdeckung in den Bereichen Stoffwechsel- und Infektionskrankheiten konzentrieren
Hamburg, 10. Juli 2024:
Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) gab heute bekannt, dass das Unternehmen eine mehrjährige ......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.07.2024
EVT
LISTED
XETR
Evotec and Pfizer collaborate to advance drug discovery in France
News Preview
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases
Hamburg, Germany, 10 July 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced it has entered into a multi-year master research collaboration and option and licens......
Themefolio
Profiler
Peergroup
© Globe Newswire
10.07.2024
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone
News Preview
STOCKHOLM, SWEDEN – July 10, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition has conducted a capital raise, implemented as a convertible loan with attached share options,for the continued development of its drug candidate golexanolone. Karolinska Development participates as part...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
